Cyclerion Therapeutics Inc
CYCN1.100USD
+0.020+1.85%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
4.06MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cyclerion Therapeutics Inc Unternehmen
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Cyclerion Therapeutics Inc Informationen
BörsenkürzelCYCN
Name des UnternehmensCyclerion Therapeutics Inc
IPO-datumMar 18, 2019
CEOGraul (Regina M)
Anzahl der mitarbeiter1
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse301 Binney Street
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon16176217722
Websitehttps://www.cyclerion.com/
BörsenkürzelCYCN
IPO-datumMar 18, 2019
CEOGraul (Regina M)
Führungskräfte von Cyclerion Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+1650.00%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+1650.00%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Hecht (Peter M)
14.25%
J. Wood Capital Advisors LLC
4.63%
American Endowment Foundation
3.39%
Invus Public Equities Advisors, LLC
2.96%
Graul (Regina Margaret)
1.42%
Andere
73.35%
Aktionäre
Aktionäre
Anteil
Hecht (Peter M)
14.25%
J. Wood Capital Advisors LLC
4.63%
American Endowment Foundation
3.39%
Invus Public Equities Advisors, LLC
2.96%
Graul (Regina Margaret)
1.42%
Andere
73.35%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
18.74%
Corporation
8.02%
Investment Advisor
5.71%
Investment Advisor/Hedge Fund
0.95%
Hedge Fund
0.40%
Research Firm
0.02%
Andere
66.15%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
33
277.64K
23.79%
--
2025Q3
36
277.64K
28.05%
-103.98K
2025Q2
36
381.62K
29.96%
-10.58K
2025Q1
53
392.20K
30.91%
-599.93K
2024Q4
57
398.50K
41.58%
-660.57K
2024Q3
62
1.11M
44.54%
-7.58K
2024Q2
66
1.10M
44.98%
-18.58K
2024Q1
76
1.12M
48.61%
-196.27K
2023Q4
83
1.12M
54.12%
-3.34K
2023Q3
98
1.12M
59.61%
-44.82K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Hecht (Peter M)
559.20K
14.25%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
4.63%
--
--
Aug 01, 2025
American Endowment Foundation
133.03K
3.39%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
2.96%
--
--
Sep 30, 2025
Graul (Regina Margaret)
55.78K
1.42%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.27%
--
--
Apr 21, 2025
DRW Securities, LLC
43.62K
1.11%
+43.62K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
37.16K
0.95%
+4.42K
+13.51%
Sep 30, 2025
Higgins (Michael J)
30.74K
0.78%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.6%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
